And we bring together people to really lean into that vision. And we’re not apologetic about it. We believe that somebody has to be trying to make this space not just a little bit better, but a lot better. And we’re thankful not only that Recursion is doing that, but that there are many other TechBio companies and many other companies in the biopharma industry who are making big bets on how the future could look extraordinarily different from how it looks today. All right. Next question from Steve Deckert [ph]. Do you have a rough timeline of when you might submit an IND for Target Epsilon? Thanks, Steve. We’re entering IND-enabling studies at this time. We just advanced that program here in the last week or so. So I think we’ll be able to give you a better timeline for that in the coming quarters.
But I know the team knows that I’m never satisfied and that speed with quality is what we’re aiming for with that program and every other one at Recursion. All right. Now we have a question from Steven Greenwood who asks, would you consider looking at multiple sclerosis and the issue of remyelinization? Steven, that’s a great question. And certainly I can’t talk about the specific areas of neuroscience that we may collaborate on with Roche=Genentech. But what I will say is that an important limitation of the platform that we built today at Recursion is that it is not yet built, I think, to build models of complex multi-organ systems or tissue systems. It’s really built today to understand in a very deep way cell-type autonomous biological mechanisms and we’re working on that.
We’ve got spheroid models and organoid models, both internal at Recursion and potentially through partnerships that we could be working on in the future that think will move us in that direction. But if I’m very honest today, I don’t think Recursion would be best suited to go after MS or remyelination, though certainly we’ll be working with our partners at Roche & Genentech to take this platform in whatever direction they’re most excited to drive it. We certainly know that there’s a high degree of unmet need in that space. All right. Next up, we have a question from Steven Ma [ph] who asks, on causal AI modeling with Tempus data, will it be used for internal drug discovery efforts or partners or both? Any change in BD discussions post-Tempus and any economics?
Great. So Steven, the economics are both in the deck here and in our filings. I’ll let you take a look at those just for the sake of time because we’re almost out of time here. What I do want to say, though, is absolutely we will be driving our causal AI models for our own internal programs, as well as for closely partnered programs at Recursion. So for example, in the context of our oncology collaboration with Bayer or our oncology collaboration with Roche & Genentech, we are able to train models on the Tempus data that we deploy for specific programs with those partners. What we’re not is sort of resell the data or memorize the data from Tempus and act as a conduit without a real skin in the game partnership. But when we’ve got a deep, robust partnership like we do with Roche & Genentech or with Bayer, we are absolutely allowed to take those learnings and advance them forward.
And one thing I’ll say, this year we acquired two companies, we built exciting new foundation models, we signed the Tempus deal and we’ve been very upfront with our partners that we intend, whenever possible, to bring all of those updates into our collaborations as fast as possible because we’re incentivized to drive medicines to patients with our partners. All right, last couple questions here. Here we are looking at CCM. Gil’s asking, what can you guide, if any, on the upcoming CCM readout? Gil, all we’re guiding at this time is that we’re going to have preliminary or I should say topline safety, tolerability and exploratory efficacy coming out in Q3. And we’re excited. We hope, of course, that those data are positive, that they lead us to be able to advance that program forward for this important area of unmet need.
But we know that regardless of what those data are, they’re going to help us improve our platform and to learn and grow as a company. Next up from NK [ph], how is Recursion thinking about commercializing its CCM program if the data is very positive? Great question, NK. We’ve got a broad commercialization strategy here at Recursion. We do believe that some of our early programs, if they are successful, could be robust opportunities for us to outlicense, sell, or otherwise partner those programs so that we can bring money back into the company to create a self-sustaining platform. Because unlike many other biopharma companies who are focused on one or two exciting programs, we believe that on average, every program at Recursion should be better than the one before it.
And if we truly believe that, we should be willing to sell or license our early programs if they’re successful in order to subsidize and pay for the next five, the next 10, the next 20 programs that we advance at Recursion and so CCM could be a good candidate for that. Now, over the intermediate or longer term, we’ll have to see how the industry moves. We’ve been generally disappointed with the adoption of some of these technology tools until very, very recently, really until the last 12 months to 18 months, where it feels like the industry is finally starting to get really excited about the potential for ML and AI. And so depending on how fast the industry goes, we may decide one day to actually take our programs forward and commercialize them.
But I can tell you, if we do that, it is very unlikely we will commercialize those programs the way it’s done today. I think we see lots of opportunities and you’re starting to see even larger companies like Lilly doing a direct-to-payer, direct-to-consumer kind of play and I could imagine Recursion focusing on something like a membership model to drive the incentives to physician in favor of the patients and in favor of using all of Recursion ‘s molecules, but we’re really talking about the intermediate- to long-term there. All right. Looks like the team has sent over a final question due to time. If your company was an animal, what animal would it be? This question comes from Johnny Gray [ph]. We’ll end on a funny note. Obviously, our company would be an octopus.
And you can see here when we got our first Phase 2 program, our first patient dosed in our first Phase 2, I promised the company that I would get a tattoo to mark that milestone, which we hope will be the first of many. And the octopus plays a very important internal role of Recursion and I think it’s the perfect animal for us. So thank you, Journey, for that funny last question.
Chris Gibson: Well, I hope everybody enjoyed this first earnings learnings call at Recursion. We intend to do this over the coming quarters. And we got a lot of potential milestones in 2024 and beyond. So I think these are going to be really exciting. I’m going to have other executives join me on future learning calls. And if you have suggestions, ways we can make this better, we want this to be adaptive. We want this to be accessible and so please reach out with that feedback on our social media platforms. Thanks everybody for tuning in and I look forward to seeing you again really, really soon.
